Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of the latest announcement, the company has bought back a total of 2,933,372 securities, with an additional 1,938 securities purchased on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and other central nervous system conditions. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: 3.11%
Average Trading Volume: 1,218
Technical Sentiment Signal: Sell
Current Market Cap: $1.03B
See more insights into NEU stock on TipRanks’ Stock Analysis page.